Form 4 for GNLX GENELUX Corp
Accepted 2023-11-22 00:00:00 ET · period of report 2023-11-21 · accession 0001209191-23-056455 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-22 | 2023-11-21 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale | $10.26 | -18.7K | 69.3K | -21% | -$191.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-21 | S | D | 18,665 | $10.26 | 69,335 | D | — | — | (F1) The weighted average sale price for the transaction reported was $10.2628, and the range of prices were between $9.91 and $10.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |